Basiliximab: Clinical Trials

8 trials of Basiliximab, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

4 completed, 2 unknown, 1 active not recruiting, 1 terminated. 8 Phase 1, 3 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 18Completed 4, Unknown 2, Active not recruiting 1, Terminated 1
Phase 23Unknown 2, Terminated 1

Follow Basiliximab: new trials by email Literature Review of Basiliximab trials Research Report on Basiliximab

Trials (filtered) newest first · largest first

All 8 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
90Y-DOTA-anti-CD25 Basiliximab, Fludarabine, Melphalan, and Total Marrow and Lymphoid Irradiation for the Treatment of High-Risk Acute Leukemia or Myelodysplastic Syndrome
Allogeneic Hematopoietic Stem Cell Transplantation, Basiliximab, Fludarabine Phosphate - Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia
Phase 1Active not recruitingCity of Hope Medical Center72022-07-192026-07-06
Effect of BM-MSCs in DCD Kidney Transplantation
bone marrow-derived mesenchymal stem cells, Saline, Induction therapy (ATG or Basiliximab) - Kidney Transplantation, Acute Kidney Tubular Necrosis
Phase 1 / Phase 2UnknownFirst Affiliated Hospital, Sun Yat-Sen University1202015-10-012015-09-28
Effect of SVF Derived MSC in DCD Renal Transplantation
SVFderived MSC transplantations, Basiliximab - Uremia
Phase 1 / Phase 2UnknownFuzhou General Hospital1202014-12-012015-07-08
Radiolabeled Monoclonal Antibody Therapy and Combination Chemotherapy Before Stem Cell Transplant in Treating Patients With Primary Refractory or Relapsed Hodgkin Lymphoma
basiliximab, carmustine, etoposide - Recurrent Adult Hodgkin Lymphoma
Phase 1CompletedCity of Hope Medical Center252013-02-132026-10-15
Vaccine Therapy and Basiliximab in Treating Patients With Acute Myeloid Leukemia in Complete Remission
basiliximab, WT1 126-134 peptide vaccine, Montanide ISA 51 VG - Adult Acute Myeloid Leukemia in Remission, Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities
Phase 1CompletedUniversity of Chicago72011-12-052018-03-09
Stem Cell Transplantation for Patients With Multiple Myeloma
G-CSF, Plerixafor, Apheresis - Myeloma
Phase 1CompletedUniversity of Chicago302011-07-122025-11-05
Mesenchymal Stem Cells Under Basiliximab/Low Dose RATG to Induce Renal Transplant Tolerance
Mesenchymal stem cells infusion, Basiliximab,Methylprednisolone,RATG ,Cyclosporine ,Mycophenolate mofetil, Basiliximab, Methylprednisolone,RATG,Cyclosporine,Mycophenolate mofetil - Kidney Transplant
Phase 1 / Phase 2TerminatedMario Negri Institute for Pharmacological Research42008-05-012023-12-04
Basiliximab in Treating Patients With Newly Diagnosed Glioblastoma Multiforme Undergoing Targeted Immunotherapy and Temozolomide-Caused Lymphopenia
RNA-loaded dendritic cell vaccine, basiliximab - Malignant Neoplasms Brain
Phase 1CompletedGary Archer Ph.D.342007-04-242021-03-09

Conditions studied

Brain Neoplasms (1)  ·  Congenital Abnormalities (1)  ·  Glioblastoma (1)  ·  Gliosarcoma (1)  ·  Hodgkin Disease (1)  ·  Kidney Tubular Necrosis, Acute (1)  ·  Leukemia, Myeloid, Acute (1)  ·  Myelodysplastic Syndromes (1)  ·  Neoplasms, Plasma Cell (1)  ·  Precursor Cell Lymphoblastic Leukemia-Lymphoma (1)  ·  Reperfusion Injury (1)  ·  Uremia (1)

Sponsors

City of Hope Medical Center (2)  ·  University of Chicago (2)  ·  First Affiliated Hospital, Sun Yat-Sen University (1)  ·  Fuzhou General Hospital (1)  ·  Gary Archer Ph.D. (1)  ·  Mario Negri Institute for Pharmacological Research (1)

Countries

United States (5)  ·  China (2)  ·  Italy (1)

Top investigators

Alessandro Rambaldi, MD (1)  ·  Changxi Wang, M.D., Ph.D (1)  ·  Eileen Smith (1)  ·  Giuseppe Remuzzi, MD (1)  ·  Hongtao Liu (1)  ·  Jeffrey Y Wong (1)  ·  Marina Noris, CH Ph (1)  ·  Martino Introna, MD (1)  ·  Michael Bishop, MD (1)  ·  Mustafa Khasraw, MD (1)  ·  Norberto Perico, MD (1)  ·  Tan Jianming, MD, PhD (1)

Results publications

PMID 20930086, PMID 21768296, PMID 23738760, PMID 29344432, PMID 29963053, PMID 31940591, PMID 34638132

NIH funding

2009 (1), P01CA030206 (1), P30CA014236 (1), P30CA033572 (1), P50CA108786 (1), R21CA185875 (1)